Influence of donor C3 allotype on late renal-transplantation outcome.

BACKGROUND The complement system has a critical role in both the innate and the adaptive immune responses. In humans, C3 exists as two main allotypes, F (fast) and S (slow), which are known to affect the incidence of inflammatory disease. We conducted a study to address the influence of these alleles on late renal-graft outcome. METHODS We determined the C3 allotypes of 662 pairs of adult kidney donors and recipients from 1993 through 2002 and then related C3F/S polymorphism status to demographic and clinical outcome data. The median length of follow-up was 3.3 years. RESULTS Analysis of 513 pairs of white donors and recipients identified 113 C3S/S recipients of a C3S/F or a C3F/F kidney and 179 C3S/S recipients of a C3S/S kidney. Graft survival was significantly better with a C3F/F or C3F/S donor allotype than a C3S/S allotype (P=0.05). The hazard ratio for graft loss of C3S/S kidneys, as compared with C3F/F or C3F/S kidneys, was 2.21 (95 percent confidence interval, 1.04 to 4.72; P=0.04). The graft function of C3F/F or C3F/S donor kidneys was significantly better than that of C3S/S donor kidneys (P<0.001). The effect of the C3F allele was specific to recipients who did not themselves possess this allele. Multivariate analysis excluded effects of other factors known to influence graft outcome. CONCLUSIONS Expression of C3 alleles by donor renal cells appears to have a differential effect on late graft outcome. Among white C3S/S recipients, receipt of a C3F/F or C3F/S donor kidney, rather than a C3S/S donor kidney, is associated with a significantly better long-term outcome. These findings suggest that the two alleles have functional differences.

[1]  Wuding Zhou,et al.  Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells. , 2006, Blood.

[2]  Piet Gros,et al.  Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.

[3]  A. Valujskikh,et al.  Decay-accelerating factor modulates induction of T cell immunity , 2005, The Journal of experimental medicine.

[4]  D. Goldsmith,et al.  Low-Dose Mycophenolate Mofetil is an Effective and Safe Treatment to Permit Phased Reduction in Calcineurin Inhibitors in Chronic Allograft Nephropathy , 2005, Transplantation.

[5]  A. Kirk,et al.  Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. , 2004, Kidney international.

[6]  R. Hargreaves,et al.  Complement activation regulates the capacity of proximal tubular epithelial cell to stimulate alloreactive T cell response. , 2004, Journal of the American Society of Nephrology : JASN.

[7]  O. Wagner,et al.  Donor heme oxygenase-1 genotype is associated with renal allograft function1 , 2004, Transplantation.

[8]  P. Chowdhury,et al.  Role of the complement system in rejection. , 2003, Current opinion in immunology.

[9]  K. Murphy,et al.  Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype , 2003, Nature.

[10]  P. Chowdhury,et al.  Footprints of humoral rejection. , 2002, Current opinion in nephrology and hypertension.

[11]  F. Kronenberg,et al.  Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. , 2002, Journal of the American Society of Nephrology : JASN.

[12]  S. Sacks,et al.  Local synthesis of complement component C3 regulates acute renal transplant rejection , 2002, Nature Medicine.

[13]  M. Walport.  Complement. First of two parts. , 2001, The New England journal of medicine.

[14]  K. Abe,et al.  In situ localization of C3 synthesis in experimental acute renal allograft rejection. , 2000, The American journal of pathology.

[15]  K. Abe,et al.  Predominant role for C5b-9 in renal ischemia/reperfusion injury. , 2000, The Journal of clinical investigation.

[16]  L. Paul.  Chronic allograft nephropathy: An update. , 1999, Kidney international.

[17]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.

[18]  R. Vaughan,et al.  Contribution of renal secreted complement C3 to the circulating pool in humans. , 1998, Journal of immunology.

[19]  G. Alexander,et al.  Extrahepatic secreted complement C3 contributes to circulating C3 levels in humans. , 1996, Journal of immunology.

[20]  P. Mathieson,et al.  MOLECULAR ANALYSIS OF C3 ALLOTYPES RELATED TO TRANSPLANT OUTCOME IN HUMAN RENAL ALLOGRAFTS , 1995, Transplantation.

[21]  M. Walport,et al.  Comparison of the binding of C3S and C3F to complement receptors types 1, 2, and 3. , 1995, Journal of immunology.

[22]  G. Riethmüller,et al.  Capillary deposition of C4d complement fragment and early renal graft loss. , 1993, Kidney international.

[23]  P. Mathieson,et al.  Molecular analysis of C3 allotypes in patients with nephritic factor , 1993, Clinical and experimental immunology.

[24]  G. Füst,et al.  The role of C3 in the immune response. , 1991, Immunology today.

[25]  M. Walport,et al.  Molecular basis of polymorphisms of human complement component C3 , 1990, The Journal of experimental medicine.

[26]  P. Lachmann,et al.  The difference between human C3F and C3S results from a single amino acid change from an asparagine to an aspartate residue at position 1216 on the alpha chain of the complement component, C3. , 1989, Journal of Immunology.

[27]  C Summers,et al.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). , 1989, Nucleic acids research.

[28]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[29]  J. Winkelstein,et al.  Genetically determined variation in the complement system: relationship to disease. , 1984, The Journal of pediatrics.

[30]  H. Arvilommi.  Capacity of complement C3 phenotypes to bind on to mononuclear cells in man , 1974, Nature.

[31]  C. Alper,et al.  Genetic polymorphism of the third component of human complement (C'3). , 1968, The Journal of clinical investigation.

[32]  N. Behrendt,et al.  A novel polymorphism of human complement component C3 detected by means of a monoclonal antibody , 2004, Immunogenetics.

[33]  P. Mathieson,et al.  Molecular analysis of C3 allotypes in patients with systemic vasculitis. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  M. Rambausek,et al.  Genetic polymorphism of C3 and Bf in IgA nephropathy. , 1987, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.